黑料网

Pancreatic cancer; Surgery; Minimally invasive procedures; Perioperative management; Postoperative outcomes; Survival rates; Multidisciplinary approach

Introduction

Pancreatic cancer is one of the most aggressive malignancies, characterized by late diagnosis and poor prognosis. Surgery remains the only potential curative treatment for pancreatic adenocarcinoma, but it is associated with significant challenges, including high rates of complications and mortality [1]. The introduction of advanced surgical techniques, improved perioperative care, and enhanced recovery protocols have aimed to mitigate these challenges [2]. This review provides an in-depth analysis of the current state of pancreatic cancer surgery, examining recent advancements and their impact on patient outcomes.

Methodology

This review synthesizes findings from a comprehensive search of medical literature databases, including PubMed, MEDLINE, and Cochrane Library, focusing on studies published between 2010 and 2023. The search terms included "pancreatic cancer surgery," "minimally invasive pancreatic surgery," "perioperative management," and "postoperative outcomes [3,4]." Criteria for inclusion were studies that reported on advancements in surgical techniques, perioperative care, and patient outcomes. Both randomized controlled trials and observational studies were included to provide a broad perspective on the subject.

Results and discussion

The analysis of recent studies reveals several key findings regarding skin cancer surgery outcomes: Efficacy and Recurrence Rates surgical removal remains highly effective for most skin cancers. Mohs micrographic surgery (MMS) has demonstrated superior efficacy for BCC and SCC, with recurrence rates as low as 1-3% for primary tumors and 5-7% for recurrent tumors [5,6]. For melanoma, wide local excision with sentinel lymph node biopsy (SLNB) has been pivotal in staging and reducing recurrence. Survival Outcomes for melanoma patients, early surgical intervention with appropriate lymph node assessment significantly improves survival rates [7]. Five-year survival rates for localized melanoma exceed 90%, underscoring the importance of early detection and surgical management. Advancements in Techniques MMS have revolutionized the surgical treatment of non-melanoma skin cancers, offering precise tumor removal with maximal tissue conservation. SLNB has become standard in melanoma management, providing critical prognostic information and guiding adjuvant therapy decisions [8,9]. Integration of Adjuvant Therapies the combination of surgery with adjuvant therapies, such as immunotherapy for melanoma, has shown promising results in improving patient outcomes [10]. Neoadjuvant treatments are also being explored to shrink tumors preoperatively, enhancing surgical success. Multidisciplinary Approach the role of a multidisciplinary team, including dermatologists, surgical oncologists, pathologists, and radiologists, is crucial in optimizing treatment plans and improving outcomes for complex skin cancer cases.

Conclusion

The advancements in pancreatic cancer surgery over the past decade have significantly improved patient outcomes, with increased survival rates and better quality of life post-surgery. Minimally invasive techniques, enhanced recovery protocols, and a multidisciplinary approach have been pivotal in these improvements. Continuous research and innovation are crucial to further enhance the efficacy of surgical interventions and perioperative care. Future studies should focus on optimizing patient selection, refining surgical techniques, and integrating novel therapies to further improve prognosis for patients with pancreatic cancer. This comprehensive review underscores the dynamic nature of pancreatic cancer surgery, highlighting the progress made and the potential for future advancements. The ongoing collaboration among surgeons, oncologists, and researchers is essential in the quest to improve patient outcomes in this challenging field.

Acknowledgement

None

Conflict of Interest

None

References

1. Cai Y, Sugimoto C, Arainga M, Alvarez X, Didier ES, et al. (2014). J Immunol 192: 2821-2829.

, ,

2. Cao JY, Dixon SJ (2016). Cell Mol Life Sci 73: 2195-2209.

, ,

3. Cao Z, Qin H, Huang Y, Zhao Y, Chen Z, et al. (2022). Bioengineered 13: 4810-4820.

, ,

4. Yuan C, Rubinson DA, Qian ZR (2015). J Clin Oncol 33: 29-35.

, ,

5. Bright R (1833). Med Chir Trans 18: 1-56.

, ,

6. Everhart J, Wright D (1995)JAMA 273: 1605-1609

,

7. Vonlanthen R, Lodge P, Barkun JS, Farges O, Rogiers X, et al. (2018. Ann Surg 268: 712-724.

, ,

8. Cooper M, Newman NA, Ibrahim AM, Lam E, Herman JM, et al. (2013). J Gastrointest Surg 17: 1218-1223.

, ,

9. Strijker M, Mackay TM, Bonsing BA, Bruno MJ, van Eijck CHJ, et al. (2020). Ann Surg 271: 102-104.

, Google Scholar,

10. Ryan DP, Hong TS, Bardeesy N (2014). N Engl J Med 371: 1039-1049.

, ,